{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:46:35Z","timestamp":1790595995528,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Career Development Award in Cancer Research"},{"DOI":"10.13039\/100006545","name":"NIMHD","doi-asserted-by":"publisher","award":["K23MD017217"],"award-info":[{"award-number":["K23MD017217"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Unresectable hepatocellular carcinoma (uHCC) is a leading cause of cancer death. FDA-approved first-line systemic therapies include atezolizumab\/bevacizumab (atezo\/bev) and durvalumab\/tremelimumab (durva\/treme); however, there is a lack of comparative data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed outcomes of patients with uHCC who initiated atezo\/bev or durva\/treme between 2017 and 2024, across six institutions. Overall survival (OS) and time to treatment discontinuation (TTD) were analyzed using the Kaplan\u2013Meier and Cox models, adjusting for baseline characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four hundred fifty-two uHCC pts were included. Median age: 68\u2009years; 77% male; 81% white. Most common etiologies were viral hepatitis (38.9%) and metabolic dysfunction-associated steatohepatitis (19.5%). Disease progression was the primary reason for treatment discontinuation, atezo\/bev (56%) and durva\/treme (42%). Outcomes were not statistically significant (median OS [month, m]: 14.0 vs 14.6 [P\u2009=\u2009.66]; median TTD [m]: 4.9 vs 3.9 [P\u2009=\u2009.42] for atezo\/bev vs durva\/treme). Outcomes were significantly different between Child-Pugh classes (CP: A, B7, B8\/9, C) respectively, median OS(m): 19.0, 6.1, 5.1, 2.0 (P\u2009&amp;lt;\u2009.001); median TTD(m): 6.1, 2.3, 3.0, 1.3 (P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world study of uHCC, no significant difference in clinical outcomes was observed between atezo\/bev and durva\/treme in the first-line setting. CP scores were a key prognostic variable with both regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf286","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T01:15:15Z","timestamp":1758330915000},"source":"Crossref","is-referenced-by-count":8,"title":["First-line atezolizumab\/bevacizumab or durvalumab\/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5260-8187","authenticated-orcid":false,"given":"Ioannis","family":"Kournoutas","sequence":"first","affiliation":[{"name":"Department of Medicine, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Marell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gile","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anina","family":"Peersen","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanshi","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"VanDommelen","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Cleveland Clinic Cancer Center , Cleveland, OH 44195,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel D","family":"Kamath","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Cleveland Clinic Cancer Center , Cleveland, OH 44195,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Alabama , Birmingham, AL 35294,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Akce","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Alabama , Birmingham, AL 35294,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-9825","authenticated-orcid":false,"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[{"name":"Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center , Los Angeles, CA 90048,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Jung","family":"Chen","sequence":"additional","affiliation":[{"name":"Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center , Los Angeles, CA 90048,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"Naleid","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Peterson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Michigan , Ann Arbor, MI 48019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-1548","authenticated-orcid":false,"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Michigan , Ann Arbor, MI 48019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wee Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Cleveland Clinic Cancer Center , Cleveland, OH 44195,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-5833","authenticated-orcid":false,"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur","family":"Halfdanarson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-2103","authenticated-orcid":false,"given":"Lionel","family":"Fonkoua Kankeu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A","family":"Washburn","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin B","family":"Conboy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Torbenson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Goenka","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar K","family":"Venkatesh","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-5337","authenticated-orcid":false,"given":"Patrick","family":"Starlinger","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Roberts","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Gores","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Babiker","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Jacksonville, FL 32224,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Phoenix, AZ 85259,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Borad","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Phoenix, AZ 85259,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Phoenix, AZ 85259,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-189X","authenticated-orcid":false,"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R","family":"McWilliams","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-8735","authenticated-orcid":false,"given":"Fang-Shu","family":"Ou","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-6489","authenticated-orcid":false,"given":"Nguyen H","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"2025111119020357100_oyaf286-B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025111119020357100_oyaf286-B2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"2025111119020357100_oyaf286-B3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2025111119020357100_oyaf286-B4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"2025111119020357100_oyaf286-B5","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/evidoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"2025111119020357100_oyaf286-B6","year":"2024"},{"key":"2025111119020357100_oyaf286-B7","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/jco.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111119020357100_oyaf286-B8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"key":"2025111119020357100_oyaf286-B9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS\u2013ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO","volume":"31","author":"Chen","year":"2020","journal-title":"Ann Oncol"},{"key":"2025111119020357100_oyaf286-B10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000531744","article-title":"Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis","volume":"13","author":"Celsa","year":"2024","journal-title":"Liver Cancer"},{"key":"2025111119020357100_oyaf286-B11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025111119020357100_oyaf286-B12","doi-asserted-by":"crossref","first-page":"102179","DOI":"10.1016\/j.eclinm.2023.102179","article-title":"Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"63","author":"Kulkarni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025111119020357100_oyaf286-B13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3892\/ol.2024.14530","article-title":"Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real\u2011world practice","volume":"28","author":"Shimose","year":"2024","journal-title":"Oncol Lett"},{"key":"2025111119020357100_oyaf286-B14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/cancers12010182","article-title":"Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025111119020357100_oyaf286-B15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for Child-Pugh class B advanced hepatocellular carcinoma","volume":"9","author":"Xie","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025111119020357100_oyaf286-B16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/HEP.0000000000000030","article-title":"Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis","volume":"77","author":"El Hajra","year":"2023","journal-title":"Hepatology"},{"key":"2025111119020357100_oyaf286-B17","doi-asserted-by":"crossref","first-page":"109519","DOI":"10.1016\/j.intimp.2022.109519","article-title":"Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: a systemic review and meta-analysis","volume":"114","author":"Tian","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025111119020357100_oyaf286-B18","doi-asserted-by":"publisher","first-page":"LBA4008","DOI":"10.1200\/jco.2024.42.17_suppl.lba4008","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW","volume":"42","author":"Peter Robert","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111119020357100_oyaf286-B19","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/jco.2024.42.16_suppl.4110","article-title":"Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): final overall survival analysis of the phase 3 CARES-310 study","volume":"42","author":"Vogel","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111119020357100_oyaf286-B20","doi-asserted-by":"publisher","first-page":"oyae342","DOI":"10.1093\/oncolo\/oyae342","article-title":"Second line therapies in advanced hepatocellular carcinoma following first line atezolizumab and bevacizumab: multicenter single institution cohort experience","volume":"30","author":"Marell","year":"2025","journal-title":"Oncologist"},{"key":"2025111119020357100_oyaf286-B21","doi-asserted-by":"publisher","first-page":"1091088","DOI":"10.3389\/fonc.2022.1091088","article-title":"Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"2025111119020357100_oyaf286-B22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"2025111119020357100_oyaf286-B23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1056\/nejmcibr2106594","volume-title":"N Engl J Med","author":"Kelley","year":"2021"},{"key":"2025111119020357100_oyaf286-B24","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.3390\/cancers14133213","article-title":"Could We predict the response of immune checkpoint inhibitor treatment in hepatocellular carcinoma?","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025111119020357100_oyaf286-B25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.21037\/hbsn-21-203","article-title":"Lack of response to immunotherapy in non-alcoholic teatohepatitis related hepatocellular carcinoma","volume":"10","author":"Kudo","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025111119020357100_oyaf286-B26","doi-asserted-by":"publisher","first-page":"733530","DOI":"10.3389\/fimmu.2021.733530","article-title":"Viral status and efficacy of immunotherapy in hepatocellular carcinoma: a systematic review with meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"},{"key":"2025111119020357100_oyaf286-B27","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat Immunol"},{"key":"2025111119020357100_oyaf286-B28","doi-asserted-by":"crossref","first-page":"1166440","DOI":"10.3389\/fimmu.2023.1166440","article-title":"Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"2025111119020357100_oyaf286-B29","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.3390\/jcm12196216","article-title":"Metabolic Dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective","volume":"12","author":"Eskridge","year":"2023","journal-title":"J Clin Med"},{"key":"2025111119020357100_oyaf286-B30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"2025111119020357100_oyaf286-B31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025111119020357100_oyaf286-B32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"2025111119020357100_oyaf286-B33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/nutrit\/nuac005","article-title":"The obesity paradox in patients with colorectal cancer: a systematic review and meta-analysis","volume":"80","author":"Li","year":"2022","journal-title":"Nutr Rev"},{"key":"2025111119020357100_oyaf286-B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2022.10.013","article-title":"Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle","volume":"178","author":"Antoun","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025111119020357100_oyaf286-B35","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MEG.0000000000002581","article-title":"Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy","volume":"35","author":"Uojima","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025111119020357100_oyaf286-B36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12935-024-03532-w","article-title":"A multidimensional analysis of the impact of obesity on immune checkpoint inhibitor therapy efficacy","volume":"24","author":"Xu","year":"2024","journal-title":"Cancer Cell Int"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf286\/64318667\/oyaf286.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf286\/64318667\/oyaf286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf286\/64318667\/oyaf286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:02:12Z","timestamp":1762905732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf286\/8257810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf286","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,18]]},"article-number":"oyaf286"}}